Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy.

BACKGROUND Diabetic nephropathy (DN) is one of the major late complications of diabetes. Treatment aimed at slowing down the progression of DN is available but methods for early and definitive detection of DN progression are currently lacking. The 'Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy In TYpe 2 diabetic patients with normoalbuminuria trial' (PRIORITY) aims to evaluate the early detection of DN in patients with type 2 diabetes (T2D) using a urinary proteome-based classifier (CKD273). METHODS In this ancillary study of the recently initiated PRIORITY trial we aimed to validate for the first time the CKD273 classifier in a multicentre (9 different institutions providing samples from 165 T2D patients) prospective setting. In addition we also investigated the influence of sample containers, age and gender on the CKD273 classifier. RESULTS We observed a high consistency of the CKD273 classification scores across the different centres with areas under the curves ranging from 0.95 to 1.00. The classifier was independent of age (range tested 16-89 years) and gender. Furthermore, the use of different urine storage containers did not affect the classification scores. Analysis of the distribution of the individual peptides of the classifier over the nine different centres showed that fragments of blood-derived and extracellular matrix proteins were the most consistently found. CONCLUSION We provide for the first time validation of this urinary proteome-based classifier in a multicentre prospective setting and show the suitability of the CKD273 classifier to be used in the PRIORITY trial.

[1]  C. Licht,et al.  Chronic kidney disease: a new look at pathogenetic mechanisms and treatment options , 2014, Pediatric Nephrology.

[2]  V. Jha,et al.  Chronic kidney disease: global dimension and perspectives , 2013, The Lancet.

[3]  H. Mischak,et al.  CKD273, a New Proteomics Classifier Assessing CKD and Its Prognosis , 2013, PloS one.

[4]  J. Ioannidis,et al.  Technical aspects and inter-laboratory variability in native peptide profiling: the CE-MS experience. , 2013, Clinical biochemistry.

[5]  H. Mischak,et al.  A urinary peptide biomarker set predicts worsening of albuminuria in type 2 diabetes mellitus , 2013, Diabetologia.

[6]  G. Remuzzi,et al.  Mechanisms and treatment of CKD. , 2012, Journal of the American Society of Nephrology : JASN.

[7]  A. Vlahou,et al.  A comparison between MALDI-MS and CE-MS data for biomarker assessment in chronic kidney diseases. , 2012, Journal of proteomics.

[8]  H. Mischak.  How to get proteomics to the clinic? Issues in clinical proteomics, exemplified by CE‐MS , 2012, Proteomics. Clinical applications.

[9]  Raymond Vanholder,et al.  Implementation of proteomic biomarkers: making it work , 2012, European journal of clinical investigation.

[10]  R. MacIsaac,et al.  Urinary Proteomics for Early Diagnosis in Diabetic Nephropathy , 2012, Diabetes.

[11]  Gretchen A. Stevens,et al.  National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants , 2011, The Lancet.

[12]  P. Zürbig,et al.  Human urinary peptide database for multiple disease biomarker discovery , 2011, Proteomics. Clinical applications.

[13]  Alexandros Kalousis,et al.  Addressing the Challenge of Defining Valid Proteomic Biomarkers and Classifiers , 2010, BMC Bioinformatics.

[14]  M. Girolami,et al.  Recommendations for Biomarker Identification and Qualification in Clinical Proteomics , 2010, Science Translational Medicine.

[15]  M. Girolami,et al.  Naturally Occurring Human Urinary Peptides for Use in Diagnosis of Chronic Kidney Disease* , 2010, Molecular & Cellular Proteomics.

[16]  R. Glassock.  Debate: CON Position. Should Microalbuminuria Ever Be Considered as a Renal Endpoint in Any Clinical Trial? , 2010, American Journal of Nephrology.

[17]  H. Heerspink,et al.  Debate: PRO Position. Should Microalbuminuria Ever Be Considered as a Renal Endpoint in Any Clinical Trial , 2010, American Journal of Nephrology.

[18]  Harald Mischak,et al.  Identification and Validation of Urinary Biomarkers for Differential Diagnosis and Evaluation of Therapeutic Intervention in Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis* , 2009, Molecular & Cellular Proteomics.

[19]  A. Dominiczak,et al.  CE‐MS analysis of the human urinary proteome for biomarker discovery and disease diagnostics , 2008, Proteomics. Clinical applications.

[20]  D. Maahs,et al.  The urinary proteome in diabetes and diabetes‐associated complications: New ways to assess disease progression and evaluate therapy , 2008, Proteomics. Clinical applications.

[21]  H. Mischak,et al.  Discovery and validation of urinary biomarkers for prostate cancer , 2008, Proteomics. Clinical applications.

[22]  Chul-woo Yang,et al.  Proteomic analysis of alpha‐1‐antitrypsin in immunoglobulin A nephropathy , 2007, Proteomics. Clinical applications.

[23]  John R Raymond,et al.  Urine biomarkers predict the cause of glomerular disease. , 2007, Journal of the American Society of Nephrology : JASN.

[24]  F. Scolari,et al.  Repetitive Fragmentation Products of Albumin and α1-Antitrypsin in Glomerular Diseases Associated with Nephrotic Syndrome , 2006 .

[25]  Tom Greene,et al.  Using Standardized Serum Creatinine Values in the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration Rate , 2006, Annals of Internal Medicine.

[26]  Walter Kolch,et al.  Discovery of biomarkers in human urine and cerebrospinal fluid by capillary electrophoresis coupled to mass spectrometry: Towards new diagnostic and therapeutic approaches , 2005, Electrophoresis.

[27]  A. Bello,et al.  Chronic kidney disease: the global challenge , 2005, The Lancet.

[28]  S. Wild,et al.  Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. , 2004, Diabetes care.

[29]  W. Kolch,et al.  Mass spectrometry for the detection of differentially expressed proteins: a comparison of surface-enhanced laser desorption/ionization and capillary electrophoresis/mass spectrometry. , 2004, Rapid communications in mass spectrometry : RCM.

[30]  B. Brenner,et al.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. , 2001, The New England journal of medicine.

[31]  Philip D. Harvey,et al.  Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 , 1998, BMJ.

[32]  R. Holman,et al.  Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. , 1998 .

[33]  R. Bain,et al.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. , 1993, The New England journal of medicine.

[34]  R. Bain,et al.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. , 1993 .

[35]  J. M. DeLeo,et al.  Receiver operating characteristic laboratory (ROCLAB): Software for developing decision strategies that account for uncertainty , 1993, 1993 (2nd) International Symposium on Uncertainty Modeling and Analysis.

[36]  A. Krolewski,et al.  In patients with type 1 diabetes and new-onset microalbuminuria the development of advanced chronic kidney disease may not require progression to proteinuria. , 2010, Kidney international.

[37]  H. Mischak,et al.  Quantitative urinary proteome analysis for biomarker evaluation in chronic kidney disease. , 2009, Journal of proteome research.

[38]  A. Fournier,et al.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. , 1994, The New England journal of medicine.

[39]  R. Atkins,et al.  Two-dimensional gel electrophoresis of urinary proteins in kidney diseases. , 1990, Contributions to nephrology.